Literature DB >> 15273100

Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Dean Hickman1, Sudthida Vasavanonda, George Nequist, Lynn Colletti, Warren M Kati, Richard Bertz, Ann Hsu, Dale J Kempf.   

Abstract

Using measured free fraction and 50% inhibitory concentration (IC50) values for the human immunodeficiency virus protease inhibitors lopinavir (LPV) and ritonavir (RTV) in tissue culture media with various protein concentrations ranging from 5 to 50%, we estimated serum-free IC50 values for each drug. The range of serum-free IC50 values (0.64 to 0.77 ng/ml for LPV and 3.0 to 5.0 ng/ml for RTV) did not exhibit a trend with increasing protein concentrations, despite a 10-fold difference in the free fraction value (0.006 to 0.063) for LPV and a 5-fold difference in the free fraction value (0.013 to 0.057) for RTV. The mean serum-free IC50 by the MTT-MT4 assay (0.69 ng/ml for LPV and 4.0 ng/ml for RTV) may be the most accurate parameter for the estimation of the inhibitory quotient (IQ), a relative measure of in vivo potency defined as the ratio of the minimal free drug concentration in plasma (C(trough,free)) for a specific patient population and the serum-free IC50. Using this approach, we calculated the average IQs for protease inhibitor-naïve patients for LPV and RTV to be 67 and 5.6, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273100      PMCID: PMC478510          DOI: 10.1128/AAC.48.8.2911-2917.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer.

Authors:  E D Matayoshi; G T Wang; G A Krafft; J Erickson
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

2.  Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.

Authors:  J A Bilello; G L Drusano
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

3.  Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  J A Bilello; P A Bilello; K Stellrecht; J Leonard; D W Norbeck; D J Kempf; T Robins; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

Authors:  J A Bilello; P A Bilello; M Prichard; T Robins; G L Drusano
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

5.  Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

Authors:  Nancy Shulman; Andrew Zolopa; Diane Havlir; Ann Hsu; Cheryl Renz; Sheila Boller; Ping Jiang; Richard Rode; Joel Gallant; Elizabeth Race; Dale J Kempf; Eugene Sun
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Authors:  D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.

Authors:  J K Lazdins; J Mestan; G Goutte; M R Walker; G Bold; H G Capraro; T Klimkait
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

8.  Ex vivo protein binding of clindamycin in sera with normal and elevated alpha 1-acid glycoprotein concentrations.

Authors:  M B Kays; R L White; G Gatti; J G Gambertoglio
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

9.  Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness.

Authors:  J W Paxton; R H Briant
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

10.  Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels.

Authors:  K Morita; A Yamaji
Journal:  Ther Drug Monit       Date:  1995-04       Impact factor: 3.681

View more
  7 in total

1.  Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.

Authors:  Hongmei Mo; Martin S King; Kathryn King; Akhteruzzaman Molla; Scott Brun; Dale J Kempf
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Authors:  Kristine B Patterson; Julie B Dumond; Heather A Prince; Amanda J Jenkins; Kimberly K Scarsi; Ruili Wang; Stephanie Malone; Michael G Hudgens; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

3.  Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

Authors:  Edward P Acosta; Kay L Limoli; Lan Trinh; Neil T Parkin; Jennifer R King; Jodi M Weidler; Ighovwerha Ofotokun; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

4.  Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.

Authors:  José R Santos; José A Muñoz-Moreno; José Moltó; Anna Prats; Adrià Curran; Pere Domingo; Josep M Llibre; Daniel R McClernon; Isabel Bravo; Jaume Canet; Victoria Watson; David Back; Bonaventura Clotet
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

5.  Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

Authors:  J Chen; S Malone; H M A Prince; K B Patterson; J B Dumond
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-22

6.  Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.

Authors:  Aarzoo Thakur; Shawn Pei Feng Tan; James Chun Yip Chan
Journal:  Clin Pharmacol Ther       Date:  2020-10-06       Impact factor: 6.903

Review 7.  Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.

Authors:  Marta Boffito; David J Back; Charles Flexner; Peter Sjö; Terrence F Blaschke; Peter W Horby; Dario Cattaneo; Edward P Acosta; Peter Anderson; Andrew Owen
Journal:  Clin Pharmacol Ther       Date:  2020-11-21       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.